Anemia of Chronic Kidney Disease Market Is Expected To Grow During the Forecast Period (2019-2032), DelveInsight

This Anemia of Chronic Kidney Disease Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Anemia of Chronic Kidney Disease Market report analysis.

Key takeaways from the Anemia of Chronic Kidney Disease Market Research Report
• According to NHANES survey, the prevalence of anemia increased with stage of CKD, from 8.4% at stage 1 to 53.4% at stage 5. A total of 22.8% of CKD patients with anemia reported being treated for anemia within the previous 3 months-14.6% of patients at CKD stages 1-2 and 26.4% of patients at stages 3-4.
• According to the study conducted by Steven F. et al. 2018, in patients with stage 3 CKD, 22.2% of patients with diabetes were anemic, increasing to 52.4% in stage 4 CKD.
• According to available literature, no gender bias was reported in case of Anemia in chronic kidney disease.

For further information on the market impact by therapies, download the Anemia of Chronic Kidney Disease Market Share @ https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anemia of Chronic Kidney Disease Epidemiology Insights

Anemia in chronic renal disease is a multifactorial condition, the widely accepted etiology being decreased renal production of erythropoietin, the hormone that is responsible for the stimulation of red blood cells production. Decreased erythropoietin has recently linked with down regulation of hypoxia-inducible factor (HIF), a transcription factor that regulates gene expression of erythropoietin. Other mechanisms include uremia (leading to RBC deformity responsible for hemolysis), folate and vitamin B12 deficiency, iron deficiency, bleeding due to dysfunctional platelets, and rarely blood loss from hemodialysis.

Anemia of Chronic Kidney Disease Epidemiology Segmentation in the 7MM
• Total Anemia of Chronic Kidney Disease Prevalent Cases
• Anemia of Chronic Kidney Disease Diagnosed and Treatable Population
• Total Anemia of Chronic Kidney Disease Prevalent Cases
• Anemia of Chronic Kidney Disease Age-specific Prevalent Cases
• Total Anemia of Chronic Kidney Disease Prevalent Cases in different stages

Anemia of Chronic Kidney Disease Treatment Market
Currently, the treatment paradigm for Anemia in Chronic Kidney Disease involves use of Iron therapies, Erythropoietin stimulating agent (ESA) therapies, Red Blood Transfusions, Vitamin B12 & Folic Acid Supplements and nutrition. ESAs and iron therapies are the most potent and commonly followed treatment procedures for anemia associated with Chronic Kidney Disease. ESAs are used to stimulate erythropoiesis by either directly or indirectly acting on the erythropoietin receptor. There are two types of ESA therapies available in the United States, Europe and Canada named as Epogen (Epoetin Alfa) and Aranesp (Darbepoetin Alfa) for the treating anemia associated due to chronic kidney disease.

Anemia of Chronic Kidney Disease Market Insights
According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Anemia commonly occurs in people with chronic kidney disease (CKD) which results into permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD, when someone has 20 to 50 percent of normal kidney function. Anemia tends to worsen as CKD progresses. Most people who have total loss of kidney function, or kidney failure, have anemia.

Anemia of Chronic Kidney Disease Market Forecast
The development of recombinant EPO followed by erythropoiesis-stimulating agents (ESAs) revolutionized the management of anemia in CKD. Although initially instituted to avoid transfusions, they were soon known to have various positive effects, including improved survival and quality of life, improved cardiac function and mortality associated with it, lower hospitalizations,and lower costs. Recombinant human erythropoietin and darbepoetin alfa are the two ESAs generally used in the management of anemia in CKD. They are fairly similar in efficacy and side effect profile, except for the longer half-life of darbepoetin alfa, thus allowing for less frequent dosing.

Read more for Anemia of Chronic Kidney Disease market research report offering- https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anemia of Chronic Kidney Disease Market Size
The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period. Expected launch of Vadadustat, Daprodustat shall fuel the growth of the market during the forecast period, i.e., 2022-2032

Anemia of Chronic Kidney Disease Market Dynamics
Traditional molecules for intravenous administration may cause rare but fatal anaphylactic reactions (especially for high molecular weight iron dextran), severe hypotension due to 'labile' iron (iron sucrose or iron gluconate) or need to be given at repeated small doses with a long infusion time in order to avoid toxicity (iron gluconate and iron sucrose). In order to avoid this several key players such as Akebia Therapeutics, GlaxoSmithKline, Astellas Pharma, FibroGen, Inc and many others are working on developing therapies for treatment of Anemia in Chronic Kidney Disease.

Table of Content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis for Anemia of Chronic Kidney Disease
4. Anemia of Chronic Kidney Disease Market Overview at a Glance
5. Anemia of Chronic Kidney Disease Disease Background and Overview
6. Patient Journey
7. Anemia of Chronic Kidney Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Anemia of Chronic Kidney Disease Unmet Needs
10. Key Endpoints of Anemia of Chronic Kidney Disease Treatment
11. Anemia of Chronic Kidney Disease Marketed Products
12. Anemia of Chronic Kidney Disease Emerging Therapies
13. Anemia of Chronic Kidney Disease Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Anemia of Chronic Kidney Disease Market Outlook
16. Access and Reimbursement Overview of Anemia of Chronic Kidney Disease
17. KOL Views
18. Anemia of Chronic Kidney Disease Market Drivers
19. Anemia of Chronic Kidney Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

For any query, just connect with our Business Consultant @ https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.